News >

Daratumumab Regimen Maintains Favorable Performance in Relapsed/Refractory Myeloma

Published: Wednesday, Dec 20, 2017

Meletios Dimopoulos, MD
Meletios Dimopoulos, MD
Progression-free survival (PFS) remained superior over time in patients with relapsed/refractory multiple myeloma treated (RRMM) treated with combination therapy that included the anti-CD38 antibody daratumumab (Darzalex), according to an updated analysis of the POLLUX trial.

“These updated findings continue to support the use of DRd in patients with relapsed and refractory multiple myeloma,” Dimopoulos concluded.
Dimopoulos MA, White DJ, Benboubker L, et al. Daratumumab, lenalidomide, and dexamethasone (drd) versus lenalidomide and dexamethasone (rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of POLLUX. Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 739.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x